Back to top

The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 13, 2016 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include iShares Nasdaq Biotechnology (IBB - Free Report) , Biogen ((BIIB - Free Report) , Alexion Pharma ((ALXN - Free Report) , BioMarin Pharma ((BMRN - Free Report) and Regeneron ( (REGN - Free Report) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

4 Stocks That Crushed the Biotech ETF (IBB - Free Report) Last Week

Although biotech has been a strong area of the market for quite some time, the past year has been a brutal stretch for this segment. In fact, the top biotechnology ETF ((IBB - Free Report) ) has seen a loss of roughly 25.5% in the past 52 weeks, making for a massive underperformance when compared to the broad markets in the same time frame.

And while there has been a bit of a comeback lately, the last few trading days have certainly put an end to that, as IBB has lost nearly five percent in the past five trading sessions.

But which stocks in particular have been driving this horrendous return as of late for this popular ETF? The following stocks are definitely the culprits as they have all lost more than the overall ETF with several slumping more than 10% in the time frame. Let’s take a quick look at a few of the biggest contributors to IBB’s underperformance as of late below:

Biogen ( (BIIB - Free Report)

Biogen shares have been in trouble lately thanks to a weak report on its MS drug results. The Phase 2 trial failed to meet both its primary and secondary endpoints and shares of BIIB plunged as a result (see Why is Biogen Stock Plunging Today?).

The stock remains a Zacks Rank #3 (Hold), while it has a VGM Score of ‘A,’ so fundamentals are still looking promising for this stock despite the recent drop.

Alexion Pharma ( (ALXN - Free Report)

More poor drug trial news to report back on, as ALXN suffered from a Phrase III letdown in its Soliris drug, as this missed its primary efficacy endpoint. Shares sold off significantly as a result of this release, and it is especially disappointing since it comes in Phase III (see Alexion’s Soliris Misses Phase III Primary Efficacy Endpoint ).

The stock is currently a Zacks Rank #4 (sell) while it has Value and Growth Style Scores of ‘D’ so there are definitely better prospects out there in the biotechnology world right now.

BioMarin Pharma ( (BMRN - Free Report)

And BioMarin struggled as its main competitor in the Muscular Dystrophy market, Sarepta, saw some somewhat promising news from the FDA. This hope for SRPT along with BioMarin’s woes in the space, lead many investors to continue their exodus out of BMRN shares which was to IBB investors’ detriment yet again (see Sarepta Asked to Provide Dystrophin Data on Eteplirsen ).

This stock is also a Zacks Rank #3 (hold), but the quarterly Earnings ESP is plunging, coming in at -13.5%. This suggests that the most recent estimates have been pretty weak for BMRN and that a downgrade may be on the horizon if this trend continues.

Regeneron ( (REGN - Free Report)

This was a bit of a surprise addition to the list of biggest losers on the week, as REGN actually reported positive results from a Phase III trial. However, the perception of the broader space has swung negative and REGN was unable to escape the downturn, falling more than 7% on the week (See Biotech Stock Roundup for more info).

Arguably shares had run up a bit too high in the preceding month and this was just a bit of a snap back to reality. Still, this remains a decent choice in the space thanks to solid EPS growth projections and a Zacks Rank #3 (Hold). And unlike others on the list, it has been seeing some relatively positive news lately.

Bottom Line

The four components listed above make up roughly one-fifth of the total exposure in IBB so they are bound to have a big impact on its overall performance. Investors in IBB will definitely need to see a turnaround here before the fund can make a comeback, and return to its storied past.

However, you could easily argue that the boom is starting to fade in the biotech sector, and especially so given the coming political headwinds for the space. Given that, it may be time to look to other health care ETFs for now, at least until the firestorm dies down in this often-volatile corner of the stock market.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in